RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

In the study (n=9,785) the two monoclonal antibodies casirivimab and imdevimab (REGEN-COV) improved the 28 day mortality of hospitalised COVID-19 patients seronegative at baseline vs usual care (24% vs 30%, HR 0.80, 95%CI 0.70-0.91).

Oxford University